INNOVATIVE PEDIATRIC ORAL FORMULATIONS FOR SECOND LINE TUBERCULOSIS DRUGS
$1,499,998N44FY2021AINIH
Luna Innovations, Inc., Roanoke VA
Investigators
Abstract
To develop pediatric formulations of tuberculosis therapeutics.
View original record on NIH RePORTER →